tailieunhanh - Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

We report the re-biopsied diagnosis of a patient with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive lung adenocarcinoma successfully treated with ceritinib 450 mg/day taken with food following disease progression and gastrointestinal intolerance to crizotinib. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN